Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined ...

Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from ...

"I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, ...

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was extreme. "I ...